Trending...
- "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience - 292
- New Slotozilla Project Explores What Happens When the World Goes Silent - 227
- Ventura College Launches County's First Speech-Language Pathology Assistant Program - 211
Semi-quantitative measurement of activation of human NFkB p65 in nuclear extracts or cell lysates.
MILPITAS, Calif. - Californer -- Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) represents a family of inducible transcription factors, which regulates many biological processes including immune responses, cell growth, apoptosis etc. This family includes five structurally related members namely NF-κB1 (or p50), NF-κB2 (or p52), RelA (or p65), RelB and c-Rel, which are normally sequestered in the cytoplasm by a family of inhibitory proteins and are inactive.
Upon stimulation, NF-κB proteins form homo- or heterodimers and are transported into the nucleus where they bind to specific DNA sequences of targeted genes and activate transcription. Traditionally, western blot is used to detect the expression of NFkB and electrophoretic mobility shift assay or reporter assays are used to measure the NFkB activity respectively. But some of these methods are time consuming, laborious, and require radioactivity. BioVision's NFkB RelA/p65 Transcription Factor Activity Assay is a 96-well plate based colorimetric assay to measure the activation of human NFkB p65 in nuclear extracts or cell lysates.
More on The Californer
The kit offers easy, rapid, sensitive and non-radioactive way to detect the activation of transcription factors in samples. In this assay, double stranded DNA sequence containing the NFkB p65 consensus binding site is coated on the 96-well plate. Active NFkB p65 in the cell lysate or the nuclear extract binds to the oligonucleotides on the plate. After the addition of RelA/p65 primary antibody that recognizes the NFkB p65-oligonucleotide complex, a HRP-conjugated secondary antibody is added followed by the addition of TMB substrate and a color signal is developed, which is measured at 450 nm.
Storage Conditions: Multiple Temperatures
USAGE: For Research Use Only! Not For Use in Humans
For more information on this Assay Kit Cat# K2093 https://bit.ly/3l2TzNM
Upon stimulation, NF-κB proteins form homo- or heterodimers and are transported into the nucleus where they bind to specific DNA sequences of targeted genes and activate transcription. Traditionally, western blot is used to detect the expression of NFkB and electrophoretic mobility shift assay or reporter assays are used to measure the NFkB activity respectively. But some of these methods are time consuming, laborious, and require radioactivity. BioVision's NFkB RelA/p65 Transcription Factor Activity Assay is a 96-well plate based colorimetric assay to measure the activation of human NFkB p65 in nuclear extracts or cell lysates.
More on The Californer
- TOM HAUSKEN: The Space Between
- California: Governor Newsom announces appointments 9.17.25
- Marketing Maven Ranked Top 10 PR Firm in Los Angeles by O'Dwyer's in 2025 Rankings Report
- California Lutheran University Receives Over $2.9 Million in Grant Funding
- Nationwide Boiler Supplies In-Stock 200K lb/hr Ultra Low NOx Boiler Package for Recovery Efforts i
The kit offers easy, rapid, sensitive and non-radioactive way to detect the activation of transcription factors in samples. In this assay, double stranded DNA sequence containing the NFkB p65 consensus binding site is coated on the 96-well plate. Active NFkB p65 in the cell lysate or the nuclear extract binds to the oligonucleotides on the plate. After the addition of RelA/p65 primary antibody that recognizes the NFkB p65-oligonucleotide complex, a HRP-conjugated secondary antibody is added followed by the addition of TMB substrate and a color signal is developed, which is measured at 450 nm.
Storage Conditions: Multiple Temperatures
USAGE: For Research Use Only! Not For Use in Humans
For more information on this Assay Kit Cat# K2093 https://bit.ly/3l2TzNM
Source: BioVision Inc
0 Comments
Latest on The Californer
- Following Trump's politicization of CDC, West Coast states issue unified vaccine recommendations — California breaks from future federal guidance with new law
- Who Will Win the 2025 WNBA Finals? OddsTrader Shares Live Betting Odds and Projections
- Silva Construction Weighs In on the Most Popular Home Design Trends for 2026
- Geeks5g Creative Marketing: The Powerhouse Behind Business Growth
- Wise Business Plans Now Serves Entrepreneurs in Los Angeles with Tailored Business Plan Writing
- Proposition 1 continues delivering support for vulnerable homeless populations in California
- Agemin Unveils Breakthrough AI Model for Biometric Age Estimation, Setting New Standards in Online Child Safety
- Turnout Secures $21M in Seed Funding to Fuel Mission to Simplify Government Bureaucracy
- Teamsters Local 2010, UC Labor Unions File Historic Lawsuit Against Trump Administration
- Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
- 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
- Leading Venture Capital Firms Recognize Wzzph Exchange's Technical Architecture and Security Framework as Industry Benchmark
- DivX Unveils Major DivX Software Update: Seamless Video Sharing and Customizable Playback Now Available
- Zoiko Supply Group Named Exclusive Distributor of Taj Mahal Rice in Caribbean, LATAM& African Market
- Software VS Paid Newsletter for Creating Side Income
- Nespolo Mechanical Helps New Mexico Families Save Thousands on Heating Costs This Fall
- Leading Digital Finance Platform YNQTL Launches Revolutionary Web3 Digital Asset Trading Platform
- Venbrook and Cognizant Partner to Modernize Claims Processing for Insurance Carriers
- IDCXS Addresses Crypto Trading Pain Points with 2 Million TPS Processing and Multi-Layer Security Architecture
- Dr. Richard Austin Heafey, PsyD, of Unfold Psychology and Heafey Practices, Accused of Misconduct